NEW YORK: Newly merged Sanofi-Aventis has tapped Euro RSCG Life to do global ad, PR, and medical education for three drugs. PR will be handled by Euro RSCG Life NRP. The assignment covers 60 countries.
Although terms of the deal weren't disclosed, the win places Sanofi-Aventis among the top five clients for Havas, the holding company of Euro RSCG.
The drugs are Lantus and Apidra, both for diabetes, and Lovenox, a blood-thinner.
Blockbuster Lovenox in particular has been a major revenue driver for the drug company, according to a third quarter earnings report.
Ron Pantello, CEO of Euro RSCG Life, said in a statement that the agency would focus on crafting a "unified, consistent" message.
A Sanofi-Aventis spokesman didn't return call for comment.
Euro RSCG is the second agency to win accounts since Sanofi purchased Aventis.
The drug company appointed a communications management team last month, with Charles Rouse at the helm in the US.